Ann Clin Microbiol 2025;29(1):4. Antibiotic resistance patterns of pathogenic Escherichia coli isolated from southeastern Korean patients with acute diarrhea from October 2023 to June 2024: a cross-sectional surveillance study

Table 3. Comparison of antibiotic resistance and multidrug resistance rates of pathogenic Escherichia coli isolates between pediatric and adult patients
Variables Pediatrics (n = 120) Adults (n = 72)
Antibiotic resistance rates, n (%)
  AMP 97 (81.0) 51 (70.4)
  AMC 67 (56.2) 17 (23.9)
  PT 28 (23.1) 2 (2.8)
  CFZ 76 (63.6) 29 (40.9)
  CTX 59 (48.8) 14 (19.4)
  CAZ 35 (28.9) 6 (8.3)
  FEP 8 (6.6) 3 (4.2)
  IPM 0 (0.0) 1 (1.4)
  MEM 0 (0.0) 0 (0.0)
  ETP 0 (0.0) 0 (0.0)
  AMK 1 (0.8) 0 (0.0)
  GEN 14 (11.6) 7 (9.9)
  CIP 19 (15.7) 10 (14.1)
  SXT 42 (34.7) 25 (35.2)
  NIT 1 (0.8) 0 (0.0)
  ATM 4 (3.3) 0 (0.0)
  FOX 4 (3.3) 0 (0.0)
  TGC 4 (3.3) 0 (0.0)
MDRa), n (%)
  EAEC 25 (43.1) 5 (18.5)
  EPEC 15 (31.9) 3 (15.0)
  ETEC 1 (11.1) 3 (13.6)

a) Samples simultaneously positive for Shiga toxin-producing E. coli, E. coli O157, and EAEC/EPEC were excluded from the MDR analysis because of the small sample size.
Abbreviations: AMP, ampicillin; AMC, amoxicillin-clavulanic acid; PT, piperacillin-tazobactam; CFZ, cefazolin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; ETP, ertapenem; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; SXT, sulfamethoxazole- trimethoprim; NIT, nitrofurantoin; ATM, aztreonam; FOX, cefoxitin; TGC, tigecycline; MDR, multidrug resistance; EAEC, enteroaggregative Escherichia coli; EPEC, enteropathogenic Escherichia coli; ETEC, enterotoxigenic Escherichia coli.